166MO Datopotamab deruxtecan (Dato-DXd)+ durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a …
P Schmid, KH Jung, PJ Wysocki, J Jassem… - Annals of …, 2022 - annalsofoncology.org
Background Patients (pts) with a/mTNBC have limited treatment options and poor prognosis.
Combining checkpoint inhibitors with 1L chemotherapy improves outcomes but only in PD-
L1+ ve a/mTNBC, emphasizing a critical need. Dato-DXd, a TROP2 antibody-drug conjugate
(ADC) with potent topoisomerase (TOPO) I inhibitor payload, elicited a 34% objective
response rate (ORR) in heavily pretreated a/mTNBC and 52% ORR in a subset naïve to
TOPO I-based ADCs. In BEGONIA, an ongoing 2-part, open-label platform study, D (an anti …
Combining checkpoint inhibitors with 1L chemotherapy improves outcomes but only in PD-
L1+ ve a/mTNBC, emphasizing a critical need. Dato-DXd, a TROP2 antibody-drug conjugate
(ADC) with potent topoisomerase (TOPO) I inhibitor payload, elicited a 34% objective
response rate (ORR) in heavily pretreated a/mTNBC and 52% ORR in a subset naïve to
TOPO I-based ADCs. In BEGONIA, an ongoing 2-part, open-label platform study, D (an anti …